Mr. Paul Mampilly is a senior editor in several of America’s significant newsletters that are published by Banyan Hill Company. The specialty of Mr. Paul Mampilly is in the appropriate research and publishing of works, aimed at helping Main Street Americans acquire wealth through investments in selected market opportunities. In this endeavor, he uses his over twenty-five-year experience as a Wall Street insider, to pinpoint small companies with promising business models and products then shares it with thousands of interested investors. The MBA graduate of Fordham University has many achievements to his name including the winning of the Templeton Foundation Investment Competition in 2008 to 2009. Read more at PRNewswire about Paul Mampilly.
In a recent article by Stock Gumshoe, Travis Johnson reviews Mr. Paul Mampilly’s teaser pitch, for his Profits, Unlimited Newsletter titled the Greatest Medical Breakthrough in History. Mr. Paul Mampilly claimed that he had identified the leading company in precision medicine revolution. He wrote that this company from the mid-Western regions of America was on the verge of realizing the most significant medical breakthrough humanity has ever seen. The company that he is vouching for is said to be making substantial leaps towards attempts in identifying medicine and treatments that work best on the individual through the extensive study of their genetic make-up. The company is trying to find means of designing medicine fit for exact DNA configuration and alleviate the possibilities of certain kinds of diseases. Read more about Paul on Interview.net.
“Moats are lame,” said Tesla CEO and billionaire Elon Musk, referring to Berkshire Hathaway CEO Warren Buffett’s central investing philosophy.https://t.co/feSl3Scr8Y#Tesla #CEO #Musk #ElonMusk #WarrenBuffett #Twitter #Moats #Economy #Trading #Investing #Stocks #StockMarket pic.twitter.com/nE1vZ9MXQG
— Paul Mampilly (@MampillyGuru) May 10, 2018
Lots of different companies fit the description provided by the renowned editor. Some are involved in the actual genetic testing or the building of equipment designed to carry out these tests while others are focused on the customization of the treatment. To shed more light on the specific company in question, he adds that it’s among the leading in the molecular diagnostics DNA sequencing industry. More specifically this company’s efforts are channeled towards establishing permanent solutions for various forms of cancer.
Stock Gumshoe deduces with certainty that the company in question is Myriad Genetics. Myriad Genetics is a personalized medicine and diagnostics company that make their fortune by processing and selling tests that identify specific cancers. They also specialize in the prediction of cancer progression and offer the most effective treatment plan. Just like Mr. Mampilly predicted, the company’s stock performed well. A series of profits has seen the company shares rise significantly. Myriad Genetics’ stock stood at $1.5 billion last summer and is currently at the $2.2 billion mark.